Most coverage of the peptide story stops at the US border. It should not. Australia is dealing with the same problem right now, and it has picked a noticeably different tool.
What Australia did
Australia's Therapeutic Goods Administration has added unapproved peptide products to its compliance focus areas for 2026 and 2027, citing increased detection of unlawful importation, supply and advertising. The stated toolkit is enforcement: warning letters, infringement notices, product seizures and forfeiture, import interventions, and in serious cases civil or criminal penalties.
That followed a consumer safety advisory issued in May telling Australians not to buy unapproved peptide products online or from overseas. The reason the TGA gave is the one we keep landing on: products referred to it by the Australian Border Force are often so poorly labelled that there is no way to verify what is actually in them.
It is not theoretical. In April, a joint operation with the Australian Border Force and Victoria Police seized more than 2 million dollars worth of steroids, performance and image enhancing drugs, and peptide products, and led to three arrests.
What enforcement reaches
We are not going to pretend this is the wrong thing to do. Intercepting mislabelled injectables at the border is a public health win, full stop, and sellers who advertise unapproved products to consumers should face consequences. Every one of those seized vials is a vial nobody injects.
What enforcement does not do is produce a verified one. A seizure removes a shipment. It does not tell a person what was in the vial they bought last month, it does not create a pharmacist who checked the dose, and it does not create a recall path if a lot goes bad. Demand does not get seized. It reroutes, usually to a seller that is harder to find than the last one.
The fork
The US is running both tracks at once. Customs enforcement is ongoing, and last week the FDA's advisory committee voted to recommend six of seven peptides for the Section 503A compounding list. That vote is a recommendation, not a rule. Formal rulemaking and a public comment window still have to happen before anything changes, and we log each step on the regulatory tracker.
That second track is the part Australia's announcement does not include, and it is the part we think matters most.
Where we stand
We disclose our interest openly at /about: Peppies is an independent, for-profit venture that would benefit only from a future legal, tested market. None of these substances has been evaluated or approved by the FDA, and we make no claim that any peptide is safe or effective. Our argument is about supply, not molecules. Enforcement alone leaves buyers with the same anonymous vial and one fewer place to ask questions. A legal, tested pathway through a licensed pharmacy is the only version of this that ends with someone accountable for what is in the bottle.
Get notified when the comment window that carries legal weight opens.